GOSS vs IMMX: fair value comparison
Gossamer Bio, Inc. and Immix Biopharma, Inc. · Updated 2026-10-19
GOSS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IMMX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, GOSS currently ranks higher by quality score.
| GOSS | IMMX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $8.77 | $7.98 |
| 12-month range | $8.77–$303.20 | $3.03–$14.47 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #240 of 301 Healthcare | #241 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: GOSS fair value analysis · IMMX fair value analysis